Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

InMed Pharmaceuticals Inc INM

InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.


NDAQ:INM - Post by User

Comment by Steveminon May 17, 2021 3:31pm
138 Views
Post# 33215618

RE:52w low - $2.60!

RE:52w low - $2.60!If more dilution is coming (as some think it is based on Colwill's comments from last week), everyone has to think about what this will do to the sp which in turn could quite possibly affect Inmed's ability to remain on the Nasdaq.
The sp is already at new 52 week lows and a cap raise at this level would destroy the sp. There are minimum requirements to stay on the Nasdaq - if you aren't familiar with what they are, i'd suggest  Googling it.
I guess they'd have to do another reverse split to keep the sp above the $4.00 required level.

Adams has really put this company in a very precarious situation. 
Actually, he has really put his shareholders in a very precarious situation.

I've never really seen such blatant ineptitude (and I was invested in Enron....)
<< Previous
Bullboard Posts
Next >>